Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma

NCT02083211 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

168

Enrollment

OTHER_GOV

Sponsor class

Conditions

Cervical Cancer Recurrent or Persistent
Palliative Treatment
Monoclonal Antibody in Cervical Cancer Treatment

Interventions

DRUG: mAb Nimotuzumab
DEVICE: Placebo

Sponsor

National Institute of Cancerología

Collaborators

[object Object]
[object Object]